BioMarin Pharmaceutical Inc
BMRN55.140USD
+0.770+1.42%
Cierre 09/18, 16:00（ET）Cotizaciones retrasadas 15 min
10.59BCap. mercado
16.11P/E TTM
Más Datos de BioMarin Pharmaceutical Inc Compañía
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Información de la empresa
Símbolo de cotizaciónBMRN
Nombre de la empresaBioMarin Pharmaceutical Inc
Fecha de salida a bolsaJul 23, 1999
Director ejecutivoMr. Alexander Hardy
Número de empleados3040
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 23
Dirección770 Lindaro Street
CiudadSAN RAFAEL
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94901
Teléfono14155066700
Sitio Webhttps://www.biomarin.com/
Símbolo de cotizaciónBMRN
Fecha de salida a bolsaJul 23, 1999
Director ejecutivoMr. Alexander Hardy
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Richard A. (Randy) Meier
Mr. Richard A. (Randy) Meier
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
120.34K
+5.85%
Mr. Alexander Hardy
Mr. Alexander Hardy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
62.99K
-53.04%
Dr. Gregory R Friberg, M.D.
Dr. Gregory R Friberg, M.D.
Executive Vice President, Chief Research & Development Officer
Executive Vice President, Chief Research & Development Officer
46.81K
+61.08%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
37.15K
+21.80%
Ms. Cristin Hubbard
Ms. Cristin Hubbard
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
30.55K
-7.36%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
23.29K
+39.97%
Dr. Athena M. Countouriotis, M.D.
Dr. Athena M. Countouriotis, M.D.
Independent Director
Independent Director
8.83K
+305.05%
Ms. Barbara W. Bodem
Ms. Barbara W. Bodem
Independent Director
Independent Director
8.83K
+305.05%
Ms. Elizabeth Mckey Anderson
Ms. Elizabeth Mckey Anderson
Independent Director
Independent Director
--
--
Mr. Timothy Walbert
Mr. Timothy Walbert
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Richard A. (Randy) Meier
Mr. Richard A. (Randy) Meier
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
120.34K
+5.85%
Mr. Alexander Hardy
Mr. Alexander Hardy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
62.99K
-53.04%
Dr. Gregory R Friberg, M.D.
Dr. Gregory R Friberg, M.D.
Executive Vice President, Chief Research & Development Officer
Executive Vice President, Chief Research & Development Officer
46.81K
+61.08%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
37.15K
+21.80%
Ms. Cristin Hubbard
Ms. Cristin Hubbard
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
30.55K
-7.36%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
23.29K
+39.97%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por negocioUSD
Nombre
Ganancia
Proporción
Voxzogo
213.75M
29.10%
Vimizim
188.35M
25.64%
Naglazyme
114.29M
15.56%
Palynziq
93.27M
12.70%
Aldurazyme
48.98M
6.67%
Otro
76.01M
10.35%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
241.69M
32.90%
Europe
229.58M
31.25%
Rest of the world
126.11M
17.17%
Latin America
88.28M
12.02%
ALDURAZYME net product revenues marked by Sanofi
48.98M
6.67%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Voxzogo
213.75M
29.10%
Vimizim
188.35M
25.64%
Naglazyme
114.29M
15.56%
Palynziq
93.27M
12.70%
Aldurazyme
48.98M
6.67%
Otro
76.01M
10.35%
Estadísticas de accionistas
Actualizado: sáb., 16 de ago
Actualizado: sáb., 16 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
9.85%
BlackRock Institutional Trust Company, N.A.
9.39%
PRIMECAP Management Company
8.21%
Dodge & Cox
7.87%
Viking Global Investors LP
6.40%
Otro
58.27%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
9.85%
BlackRock Institutional Trust Company, N.A.
9.39%
PRIMECAP Management Company
8.21%
Dodge & Cox
7.87%
Viking Global Investors LP
6.40%
Otro
58.27%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
43.86%
Investment Advisor/Hedge Fund
39.63%
Hedge Fund
7.66%
Pension Fund
3.19%
Research Firm
1.70%
Sovereign Wealth Fund
1.23%
Bank and Trust
1.17%
Individual Investor
0.75%
Venture Capital
0.34%
Otro
0.47%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
1333
195.10M
101.61%
-16.01M
2025Q1
1355
191.53M
99.87%
-20.72M
2024Q4
1336
190.53M
99.88%
-17.50M
2024Q3
1308
188.26M
98.81%
-22.17M
2024Q2
1293
192.58M
101.18%
-14.21M
2024Q1
1278
194.24M
102.38%
-11.23M
2023Q4
1294
193.16M
102.42%
-3.22M
2023Q3
1275
188.66M
100.18%
-4.68M
2023Q2
1283
185.80M
98.76%
-8.08M
2023Q1
1274
186.38M
99.36%
-9.64M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
18.92M
9.87%
-369.57K
-1.92%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
18.12M
9.45%
-16.94K
-0.09%
Mar 31, 2025
PRIMECAP Management Company
17.77M
9.27%
-415.89K
-2.29%
Mar 31, 2025
Dodge & Cox
14.96M
7.8%
+209.00K
+1.42%
Mar 31, 2025
Viking Global Investors LP
10.80M
5.63%
+289.51K
+2.75%
Mar 31, 2025
State Street Global Advisors (US)
8.46M
4.41%
-649.18K
-7.12%
Mar 31, 2025
AQR Capital Management, LLC
2.93M
1.53%
+1.64M
+127.94%
Mar 31, 2025
Geode Capital Management, L.L.C.
3.43M
1.79%
+142.47K
+4.33%
Mar 31, 2025
Norges Bank Investment Management (NBIM)
3.57M
1.86%
-49.67K
-1.37%
Dec 31, 2024
Ver más
ETFs relacionados
Actualizado: sáb., 6 de sep
Actualizado: sáb., 6 de sep
Nombre
Proporción
First Trust Mid Cap Growth AlphaDEX Fund
0%
First Trust Mid Cap Core Alphadex Fund
0%
Goldman Sachs Equal Weight US Large Cap Equity ETF
0%
AGF US Market Neutral Anti-Beta Fund
0%
iShares S&P Mid-Cap 400 Growth ETF
0%
iShares Russell 1000 Growth ETF
0%
First Trust Lunt US Factor Rotation ETF
0%
SPDR S&P 400 Mid Cap Growth ETF
0%
QRAFT AI-Enhanced US Large Cap ETF
0%
WisdomTree US LargeCap Fund
0%
Ver más
First Trust Mid Cap Growth AlphaDEX Fund
Proporción0%
First Trust Mid Cap Core Alphadex Fund
Proporción0%
Goldman Sachs Equal Weight US Large Cap Equity ETF
Proporción0%
AGF US Market Neutral Anti-Beta Fund
Proporción0%
iShares S&P Mid-Cap 400 Growth ETF
Proporción0%
iShares Russell 1000 Growth ETF
Proporción0%
First Trust Lunt US Factor Rotation ETF
Proporción0%
SPDR S&P 400 Mid Cap Growth ETF
Proporción0%
QRAFT AI-Enhanced US Large Cap ETF
Proporción0%
WisdomTree US LargeCap Fund
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
